MOC31PE binds to the tumor-associated EpCAM on the surface of cancer cells, through which it is internalized, and PE is released to trigger rapid cell death.5,6 With EpCAM being ubiquitously expressed in most epithelial cancers, MOC31PE is being developed as a promising new anticancer drug.7,8 In the recent phase I/II ImmunoPeCa trial, MOC31PE administered intraperitoneally the day after CRS-HIPEC was well tolerated, with excellent drug stability and pharmacokinetic properties and with promising long-term results.9,10. Here, EPCAM is linked to neoplasm.